About Us
Alaya.bio is a preclinical-stage biotechnology company developing in vivo CAR-T cell therapies using a proprietary targeting polymeric nanoparticle platform. We reprogram immune cells directly inside the patient’s body, removing the apheresis, ex vivo manufacturing, and reinfusion steps that today limit CAR-T to fewer than one in three eligible patients.
Our platform combines the biological efficiency of lentiviral gene delivery with the precision and modularity of synthetic polymer chemistry. The result is a single injectable product designed for scalable manufacturing, repeat dosing, and broad therapeutic reach across oncology and autoimmune disease.
Our Story
Alaya.bio was founded in July 2022 by Renaud Vaillant (CEO), Cécile Bauche (CSO), and Michel Sadelain as Scientific Co-Founder. Dr Sadelain, inaugural director of the Columbia Initiative in Cell Engineering and Therapy (CICET) at Columbia University, is the 2024 Breakthrough Prize for Life Sciences laureate, widely recognized as one of the pioneers of CAR-T immunotherapy.
Alaya.bio is developing an innovative polymeric nanoparticle platform that enables the direct targeting and reprogramming of patient immune cells inside the body.
The company’s first applications are in immuno-oncology and autoimmune disease, an “in vivo CAR-T” cell therapy that eliminates the need to extract, manipulate, and reinfuse patient cells.
